Page last updated: 2024-11-10

lysine clonixinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lysine clonixinate: a non-morphinic analgesic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clonixin lysine salt : An organoammonium salt obtained by combining clonixin with one molar equivalent of L-lysine. Used for treatment of renal colic, muscular pain and moderately severe migraine attacks. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3080836
CHEMBL ID4303711
CHEBI ID76201
MeSH IDM0099434

Synonyms (49)

Synonym
AC-1606
clonixin lysinate
06pw4m190r ,
dolalgial
unii-06pw4m190r
D07728
55837-30-4
clonixil (tn)
clonixin lysine salt
l-104
2-(2'-methyl-3'-chloroanilino)lysine nicotinate
l 104
l-lysine, mono(2-((3-chloro-2-methylphenyl)amino)-3-pyridinecarboxylate)
lysine clonixinate
l-lysine clonixinate
l-lysine 2-[(3-chloro-2-methylphenyl)amino]-3-pyridinecarboxylate
HMS2098M10
AKOS015895798
clonixin lysine salt [mi]
r-173
l-lysine, 2-((3-chloro-2-methylphenyl)amino)-3-pyridinecarboxylate (1:1)
clonixin lysine [mart.]
clonixin lysine
2-(3-chloro-o-toluidino)nicotinic acid, lysine salt
clonixin lysinate [who-dd]
CCG-221104
2-[(3-chloro-2-methylphenyl)amino]nicotinic acid--l-lysine (1/1)
(2s)-2,6-diazaniumylhexanoate 2-[(3-chloro-2-methylphenyl)amino]nicotinate
l-clonixin lysine salt
CHEBI:76201
DTXSID10204436
sr-01000872701
SR-01000872701-1
(2s)-2,6-diaminohexanoic acid; 2-[(3-chloro-2-methylphenyl)amino]pyridine-3-carboxylic acid
AS-73002
HMS3715M10
l-lysine, 2-[(3-chloro-2-methylphenyl)amino]-3-pyridinecarboxylate (1:1)
Q27145806
2-[(3-chloro-2-methylphenyl)amino]pyridine-3-carboxylic acid (2s)-2,6-diaminohexanoic acid
l-lysine compound with 2-((3-chloro-2-methylphenyl)amino)nicotinic acid (1:1)
mfcd07364029
clonixin-lysinate
l-lysinemono (2-((3-chloro-2-methylphenyl)amino)-3-pyridinecarboxylate)
CHEMBL4303711
D97791
2-(3-chloro-2-methylanilino)pyridine-3-carboxylic acid;(2s)-2,6-diaminohexanoic acid
[(5s)-5-amino-5-carboxypentyl]azanium;2-(3-chloro-2-methylanilino)pyridine-3-carboxylate
42059-11-0
l-lysine clonixinate hydrochloride

Research Excerpts

Overview

Lysine clonixinate (LC) is a drug of antiinflammatory antipyretic and analgesic activity that produces minor digestive side-effects. NSAID derived from nicotinic acid has proven to be effective in various pain syndromes such as renal colic and muscular pain.

ExcerptReferenceRelevance
"Lysine clonixinate is an analgesic drug with a so far unknown mechanism of action. "( Effects of single oral doses of lysine clonixinate and acetylsalicylic acid on platelet functions in man.
Bertram, L; Muhs, A; Nagyiványi, P; Pallapies, D; Peskar, BA; Rohleder, G, 1996
)
2.02
"Lysine clonixinate (LC) is a drug of antiinflammatory antipyretic and analgesic activity that produces minor digestive side-effects. "( Effects of lysine clonixinate on cyclooxygenase I and II in rat lung and stomach preparations.
de los Santos, AR; Di Girolamo, G; Franchi, AM; Gimeno, MA; Martí, ML, 1998
)
2.13
"Lysine clonixinate (LC) is a NSAID derived from nicotinic acid that has been proven effective in various algic syndromes such as renal colic, nerve compression, muscular pain and odontalgias."( [Intravenous lysine clonixinate for the treatment of migraine: an open pilot study].
Barbosa, J; Krymchantowski, AV, 1999
)
1.39
"Lysine clonixinate (LC) is a non-steroidal antiinflammatory agent (NSAID) with only few adverse effects. "( [Differential action of non-steroidal antiinflammatory drugs on human gallbladder cyclooxygenase and lipoxygenase].
de los Santos, AR; Di Girolamo, G; Farina, M; Franchi, A; Gimeno, MA; Martí, ML, 2000
)
1.75
"Lysine clonixinate (LC) is a NSAID derived from nicotinic acid that has proven to be effective in various pain syndromes such as renal colic and muscular pain."( Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study.
Alves, LA; Barbosa, JS; Cheim, C; Krymchantowski, AV, 2001
)
1.55
"Lysine clonixinate (LC) is a nonsteroidal anti-inflammatory drug (NSAID) with good gastrointestinal tolerance. "( [Effect of nonsteroidal antiinflammatory drugs on colonic lipoxygenase and cyclooxygenase activities from patients with colonic neoplasia].
De Los Santos, AR; Di Girolamo, G; Farina, M; Fernández de Gimeno, MA; Franchi, A; Martí, ML, 2001
)
1.75

Toxicity

ExcerptReferenceRelevance
" Only three adverse effects of light intensity were found without needing treatment, related to the manifestations of gastralgia and sleepiness."( [Analgesic-antispasmodic effect and safety of lysine clonixinate and L-hyoscinbutylbromide in the treatment of dysmenorrhea].
de la Jara Díaz, J; Hernández Bueno, JA; Llorens Torres, F; Sedeño Cruz, F, 1998
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic values were estimated by a nonlinear computer program."( Pharmacokinetics of lysine clonixinate in children in postoperative care.
Cattan, C; González-Martin, G; Zuñiga, S, 1996
)
0.62

Dosage Studied

ExcerptRelevanceReference
" The amount of radioactivity excreted in faeces was measured during a placebo baseline phase of three days, a treatment phase of five days with thrice daily dosing of ASA, ibuprofen or lysine clonixinate and a subsequent wash-out phase of five days."( Gastrointestinal blood loss induced by three different non-steroidal anti-inflammatory drugs.
Bidlingmaier, A; Hammermaier, A; Nagyiványi, P; Pabst, G; Waitzinger, J, 1995
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitorA compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
lipoxygenase inhibitorA compound or agent that combines with lipoxygenase and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of the icosanoid products hydroxyicosatetraenoic acid and various leukotrienes.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organoammonium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (40.00)18.2507
2000's11 (36.67)29.6817
2010's5 (16.67)24.3611
2020's2 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.54 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index76.26 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (49.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (53.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (6.67%)4.05%
Observational0 (0.00%)0.25%
Other12 (40.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]